Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.40 +0.05 (+3.70%)
At close: Nov 11, 2026 · 4:00 PM EST

Transcode Therapeutics (RNAZ) Preferred Stock Liabilities (2025 - 2026)

Updated

Transcode Therapeutics (RNAZ) recorded Preferred Stock Liabilities of $166.05 million in Q2 2026, up 15.9% from the prior quarter.

Analysis

Transcode Therapeutics (RNAZ) Preferred Stock Liabilities (2025 - 2026) Analysis & Trends

At the end of FY2025, Transcode Therapeutics reported Preferred Stock Liabilities of $141.54 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Transcode Therapeutics 1.37 Mn -40.52 Mn - 166.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 166.05 Mn
Mar 31, 2026 143.27 Mn
Dec 31, 2025 141.54 Mn
API Access

Transcode Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RNAZ&period=max&api_key=YOUR_API_KEY